
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomark Insights</journal-id><journal-id journal-id-type="publisher-id">Biomarker Insights</journal-id><journal-title-group><journal-title>Biomarker Insights</journal-title></journal-title-group><issn pub-type="epub">1177-2719</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2717845</article-id><article-id pub-id-type="publisher-id">bmi-2007-447</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kneller</surname><given-names>Julie M.</given-names></name><xref ref-type="aff" rid="af1-bmi-2007-447">1</xref><xref ref-type="corresp" rid="c1-bmi-2007-447"/></contrib><contrib contrib-type="author"><name><surname>Ehlen</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af2-bmi-2007-447">2</xref></contrib><contrib contrib-type="author"><name><surname>Matisic</surname><given-names>Jasenka P.</given-names></name><xref ref-type="aff" rid="af3-bmi-2007-447">3</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Dianne</given-names></name><xref ref-type="aff" rid="af2-bmi-2007-447">2</xref></contrib><contrib contrib-type="author"><name><surname>Van Niekerk</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="af4-bmi-2007-447">4</xref></contrib><contrib contrib-type="author"><name><surname>Lam</surname><given-names>Wan L.</given-names></name><xref ref-type="aff" rid="af5-bmi-2007-447">5</xref></contrib><contrib contrib-type="author"><name><surname>Marra</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="af1-bmi-2007-447">1</xref></contrib><contrib contrib-type="author"><name><surname>Richards-Kortum</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="af6-bmi-2007-447">6</xref></contrib><contrib contrib-type="author"><name><surname>Follen</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="af7-bmi-2007-447">7</xref></contrib><contrib contrib-type="author"><name><surname>MacAulay</surname><given-names>Calum</given-names></name><xref ref-type="aff" rid="af3-bmi-2007-447">3</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Steven J. M.</given-names></name><xref ref-type="aff" rid="af1-bmi-2007-447">1</xref></contrib></contrib-group><aff id="af1-bmi-2007-447"><label>1</label> Genome Sciences Centre, British Columbia Cancer Research Centre, Vancouver, BC, Canada</aff><aff id="af2-bmi-2007-447"><label>2</label> Department of Gynaecologic Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada</aff><aff id="af3-bmi-2007-447"><label>3</label> Cancer Imaging, British Columbia Cancer Research Centre, Vancouver, BC, Canada</aff><aff id="af4-bmi-2007-447"><label>4</label> Cervical Cancer Screening Program, British Columbia Cancer Agency, Vancouver, BC, Canada</aff><aff id="af5-bmi-2007-447"><label>5</label> Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, Vancouver, BC, Canada</aff><aff id="af6-bmi-2007-447"><label>6</label> Biomedical Engineering, University of Texas at Austin, Austin, TX, U.S.A</aff><aff id="af7-bmi-2007-447"><label>7</label> University of Texas M.D. Anderson Cancer Center, Department of Gynecologic Oncology and Biomedical Engineering Center, Houston, TX, U.S.A</aff><author-notes><corresp id="c1-bmi-2007-447">Correspondence: Julie M. Kneller, Genome Sciences Centre, BC Cancer Research Centre, 570 West 7th Ave – Suite 100, Vancouver, BC V5Z 4S6, Canada. Tel: (604) 707-5900 (5416); Email:<email>jkneller@bcgsc.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2007</year></pub-date><volume>2</volume><fpage>447</fpage><lpage>461</lpage><permissions><copyright-statement>© 2007 by the authors</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Sixteen longSAGE libraries from four different clinical stages of cervical intraepithelial neoplasia have enabled us to identify novel cell-surface biomarkers indicative of CIN stage. </plain></SENT>
<SENT sid="2" pm="."><plain>By comparing gene expression profiles of cervical tissue at early and advanced stages of CIN, several genes are identified to be novel genetic markers. </plain></SENT>
<SENT sid="3" pm="."><plain>We present fifty-six cell-surface gene products differentially expressed during progression of CIN. </plain></SENT>
<SENT sid="4" pm="."><plain>These cell surface proteins are being examined to establish their capacity for optical contrast agent binding. </plain></SENT>
<SENT sid="5" pm="."><plain>Contrast agent visualization will allow real-time assessment of the physiological state of the disease process bringing vast benefit to cancer care. </plain></SENT>
<SENT sid="6" pm="."><plain>The data discussed in this publication have been submitted to NCBIs Gene Expression Omnibus (GEO, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>) and are accessible through GEO Series accession number GSE6252. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>longSAGE</kwd><kwd>cervical cancer</kwd><kwd>biomarker</kwd><kwd>optical imaging</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="7" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="8" pm="."><plain>Clinical diagnosis of most cancers and their precursors is predominantly based on phenotypic markers such as appearance of cell nuclei. </plain></SENT>
<SENT sid="9" pm="."><plain>Classification and staging of disease is determined by evaluation of gross structural features, such as extent of local tumour invasion and presence of disease in other organs. </plain></SENT>
<SENT sid="10" pm="."><plain>It is now established that cancer arises as a result of successive genetic changes altering cellular processes including growth, angiogenesis, senescence, and apoptosis (Hanahan and Weinburg, 2000). </plain></SENT>
<SENT sid="11" pm="."><plain>Additionally, many cancers appear to have active inflammation and wound healing mechanisms (Chang et al. </plain></SENT>
<SENT sid="12" pm="."><plain>2004). </plain></SENT>
<SENT sid="13" pm="."><plain>Proteins taking part in these cellular mechanisms are often strong candidates for biomarkers and molecular targets. </plain></SENT>
</text></p><p><text><SENT sid="14" pm="."><plain>Cervical cancer is usually the result of a human papillomavirus (HPV) infection which initiates neoplastic progression mainly through viral oncoproteins E6 and E7 within the cervical transformation zone at the squamous/columnar junction. </plain></SENT>
<SENT sid="15" pm="."><plain>The role of HPV to the pathogenesis of cervical cancer has been addressed in recent reviews (zur Hausen, 2002; Woodman et al. </plain></SENT>
<SENT sid="16" pm="."><plain>2007). </plain></SENT>
<SENT sid="17" pm="."><plain>Many HPV types produce only productive lesions following infection and are not associated with human cancers. </plain></SENT>
<SENT sid="18" pm="."><plain>In such lesions, the expression of viral gene products is carefully regulated, with viral proteins being produced at defined times and at regulated levels as the infected cell migrates towards the epithelial surface. </plain></SENT>
<SENT sid="19" pm="."><plain>The events that lead to viral synthesis in the upper epithelial layers appear common to both the low- and high-risk HPV types. </plain></SENT>
<SENT sid="20" pm="."><plain>Virus-induced cancers most often arise at sites where productive infection cannot be suitably supported. </plain></SENT>
<SENT sid="21" pm="."><plain>Productive infection can be divided into distinct phases, with different viral proteins playing specific roles (Doorbar, 2006). </plain></SENT>
<SENT sid="22" pm="."><plain>Upon infection, normal cells gradually advance through stages of cervical intraepithelial neoplasia (CIN). </plain></SENT>
<SENT sid="23" pm="."><plain>Mild dysplasia (CINI) presents as only a subset of the low third of the epithelium appearing dysplastic, moderate dysplasia (CINII) occurs where the dysplastic cells involve about one-half of the thickness of the epithelium of the cervix, and severe dysplasia (CINIII), or carcinoma-in-situ, is described as the condition where the entire thickness of the epithelium is disordered but the abnormal cells have not yet spread below the surface. </plain></SENT>
<SENT sid="24" pm="."><plain>If carcinoma-in-situ is not treated, it will often grow into an invasive cervical cancer. </plain></SENT>
<SENT sid="25" pm="."><plain>High grade dysplasia is considered the most advanced dysplasia with atypical changes in many of the cells and a very abnormal growth pattern of the glands; some of the glands are branching or budding. </plain></SENT>
<SENT sid="26" pm="."><plain>More than 50% of the cells have large, spotted nuclei and are frequently dividing while the cellular cytoplasm is reduced and looks abnormal. </plain></SENT>
<SENT sid="27" pm="."><plain>Cancer of the cervix was one of the most common causes of cancer death for American women, but between 1955 and 1992 the number of cervical cancer deaths in the United States dropped by 74% due to the introduction of the Pap test (Papanicolaou and Traut, 1943). </plain></SENT>
<SENT sid="28" pm="."><plain>Death rates from cervical cancer continue to decline by nearly 4% per year. </plain></SENT>
<SENT sid="29" pm="."><plain>Even so, the American Cancer Society reports that in 2006, about 3,700 of the 9,710 women diagnosed with cervical cancer in the United States have died from this disease. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>HPV infection causes changes in expression levels of a wide variety of genes (Yim and Park, 2006). </plain></SENT>
<SENT sid="31" pm="."><plain>These differences in gene expression between pre-invasive neoplastic and non-neoplastic tissue give clues to the molecular basis of cancer. </plain></SENT>
<SENT sid="32" pm="."><plain>Early detection of cervical cancer based on molecular characterization would be clinically advantageous; risk of neoplastic lesion progression could be predicted and response to therapy could be monitored in real time at a molecular level. </plain></SENT>
<SENT sid="33" pm="."><plain>To monitor molecular characterisation of cancer it follows that the ability to optically image in real-time the molecular features of cancer in vivo is critical (González et al. </plain></SENT>
<SENT sid="34" pm="."><plain>1999; Rajadhyaksha et al. </plain></SENT>
<SENT sid="35" pm="."><plain>1999; White et al. </plain></SENT>
<SENT sid="36" pm="."><plain>1999; Huzaira et al. </plain></SENT>
<SENT sid="37" pm="."><plain>2001; Langley et al. </plain></SENT>
<SENT sid="38" pm="."><plain>2001; Selkin et al. </plain></SENT>
<SENT sid="39" pm="."><plain>2001; Collier et al. </plain></SENT>
<SENT sid="40" pm="."><plain>2002) and requires safe, molecular-specific contrast agents whose images can be monitored rapidly and non-invasively during their uptake and distribution. </plain></SENT>
<SENT sid="41" pm="."><plain>The analysis presented here evaluates serial analysis of gene expression (SAGE) libraries to identify novel, cell-surface gene products. </plain></SENT>
<SENT sid="42" pm="."><plain>Upon mapping of highly differentially expressed SAGE tags to their corresponding genes, the gene products are candidates for antibody testing and optical contrast agent development. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="43" pm="."><plain>Contrast Agents and Optical Imaging </plain></SENT>
</text></title><p><text><SENT sid="44" pm="."><plain>Short of prevention, improved early stage cancer diagnosis would provide the greatest benefit for cancer patients. </plain></SENT>
<SENT sid="45" pm="."><plain>Because proteins may regulate gene expression, ligand-binding properties, molecular structure and dynamics on a temporal basis, protein biomarkers have a significant impact in cancer detection and therapy as therapies are becoming targeted to specific signal transduction and metabolic pathways. </plain></SENT>
<SENT sid="46" pm="."><plain>For example, breast cancers respond to HERCEPTIN (trastuzumab) if the tumor over-expresses Her-2/neu (Baselga et al. </plain></SENT>
<SENT sid="47" pm="."><plain>2004; Ross et al. </plain></SENT>
<SENT sid="48" pm="."><plain>2004). </plain></SENT>
<SENT sid="49" pm="."><plain>In the same way, GLEEVEC (imatinib) is most effective against cancers carrying the bcr-Abl translocation (Druker, 2004) and targeted molecular cancer therapy is already used successfully for the eradication of acute leukaemia (Frater et al. </plain></SENT>
<SENT sid="50" pm="."><plain>2003; Yee and Keating, 2003). </plain></SENT>
<SENT sid="51" pm="."><plain>These examples imply that it will be important to produce biomarkers for all stages of cancer. </plain></SENT>
<SENT sid="52" pm="."><plain>Reliable diagnostics such as DNA screening and immunocytochemical analysis of known cervical neoplasia biomarkers p16INK4A and minichromosome maintenance (MCM) proteins are not implemented in vivo. </plain></SENT>
<SENT sid="53" pm="."><plain>Real-time biomarkers of the physiological state of the disease process or markers representative of treatment efficacy will bring immeasurable benefit to cancer care in terms of individualized agent selection and dosing. </plain></SENT>
<SENT sid="54" pm="."><plain>Furthermore, series of agents could be tested to determine empirically the localization of cancer and/or the most effective therapy. </plain></SENT>
</text></p><p><text><SENT sid="55" pm="."><plain>Routine clinical cancer detection employs non-specific contrast agents such as acetic acid which enhance the nuclear backscattering but are limited by small signal magnitude. </plain></SENT>
<SENT sid="56" pm="."><plain>The field of molecular imaging is rapidly developing imaging agents with high affinity and specificity for targeted biomarkers. </plain></SENT>
<SENT sid="57" pm="."><plain>These new agents allow for the possibility of disease detection earlier than is currently feasible (Weissleder, 2001; Jaffer and Weissleder, 2005). </plain></SENT>
<SENT sid="58" pm="."><plain>For example, cancer metastases missed by conventional anatomically based imaging methods may be detected in patients by molecular imaging (Harisinghani et al. </plain></SENT>
<SENT sid="59" pm="."><plain>2003). </plain></SENT>
<SENT sid="60" pm="."><plain>Optical imaging of tissue can be carried out non-invasively in real time, giving high spatial resolution (&lt;1 μm lateral resolution). </plain></SENT>
<SENT sid="61" pm="."><plain>A number of optical techniques have been established including confocal microscopy (White et al. </plain></SENT>
<SENT sid="62" pm="."><plain>1999; Collier et al. </plain></SENT>
<SENT sid="63" pm="."><plain>2005), multispectral fluorescence imaging (Andersson-Engels et al. </plain></SENT>
<SENT sid="64" pm="."><plain>1997; Ferris et al. </plain></SENT>
<SENT sid="65" pm="."><plain>2001), reflectance spectroscopy with polarised and unpolarised light (Sokolov et al. </plain></SENT>
<SENT sid="66" pm="."><plain>1999, 2002; Utzinger et al. </plain></SENT>
<SENT sid="67" pm="."><plain>2001), multispectral reflectance imaging with polarised and unpolarised light (Ferris et al. </plain></SENT>
<SENT sid="68" pm="."><plain>2001; Gurjar et al. </plain></SENT>
<SENT sid="69" pm="."><plain>2001), and fluorescence spectroscopy (Gillenwater et al. </plain></SENT>
<SENT sid="70" pm="."><plain>1998; Wagnières et al. </plain></SENT>
<SENT sid="71" pm="."><plain>1998; Ramanujam, 2000; Sokolov et al. </plain></SENT>
<SENT sid="72" pm="."><plain>2002). </plain></SENT>
<SENT sid="73" pm="."><plain>Together with emerging molecular tools (e.g. DNA screening, tissue proteomic and serum markers), biomarker imaging may soon be used for real-time screening, diagnosis, and detection of disease recurrence and progression (Rudin and Weissleder, 2003). </plain></SENT>
</text></p><p><text><SENT sid="74" pm="."><plain>Contrast agents consist of a biomarker specific probe molecule, such as an antibody, conjugated to an optically suitable label. </plain></SENT>
<SENT sid="75" pm="."><plain>By topically applying molecular specific contrast agents to tissues, the scope of molecular changes that can be probed using optical imaging is significantly enhanced. </plain></SENT>
<SENT sid="76" pm="."><plain>Presently, contrast agents based on metal nanoparticles, organic fluorescent dyes, and quantum dots coupled to monoclonal antibodies against cancer specific biomarkers are being developed (Sokolov et al. </plain></SENT>
<SENT sid="77" pm="."><plain>2003; Rahman et al. </plain></SENT>
<SENT sid="78" pm="."><plain>2005). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="79" pm="."><plain>SAGE Libraries and Tag Mapping </plain></SENT>
</text></title><p><text><SENT sid="80" pm="."><plain>The SAGE technique is capable of producing a molecular representation of cervical tissue based on expressed genes. </plain></SENT>
<SENT sid="81" pm="."><plain>SAGE is not dependent on pre-existing databases of expressed genes and so provides an independent view of gene expression profiles within the mRNA populations (Velculescu et al. </plain></SENT>
<SENT sid="82" pm="."><plain>1997). </plain></SENT>
<SENT sid="83" pm="."><plain>SAGE library construction is well documented in the literature (Velculescu et al. </plain></SENT>
<SENT sid="84" pm="."><plain>1995 and 1997; Madden et al. </plain></SENT>
<SENT sid="85" pm="."><plain>2000; Saha et al. </plain></SENT>
<SENT sid="86" pm="."><plain>2002; Pleasance et al. </plain></SENT>
<SENT sid="87" pm="."><plain>2003; Sander et al. </plain></SENT>
<SENT sid="88" pm="."><plain>2005). </plain></SENT>
<SENT sid="89" pm="."><plain>Several recent gene expression profiles of in vitro HPV-infected cultured keratinocytes and from cervical carcinoma clinical samples have proposed changes in gene expression induced by HPV and in early cervical carcinomas (Thomas et al. </plain></SENT>
<SENT sid="90" pm="."><plain>2001; Ruutu et al. </plain></SENT>
<SENT sid="91" pm="."><plain>2002; Duffy et al. </plain></SENT>
<SENT sid="92" pm="."><plain>2003; Pérez-Plasencia et al. </plain></SENT>
<SENT sid="93" pm="."><plain>2005). </plain></SENT>
<SENT sid="94" pm="."><plain>Some studies have compared normal versus tumor-induced gene expression in cervical samples with the aim of identifying potential tumor markers of clinical value (Shim et al. </plain></SENT>
<SENT sid="95" pm="."><plain>1998; Chen et al. </plain></SENT>
<SENT sid="96" pm="."><plain>2003). </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>To identify genes expressed at dissimilar levels in preinvasive neoplastic and non-neoplastic untyped cervical tissue, we analysed sixteen long-SAGE libraries; 4 from normal cervical tissue samples, 3 of a mild dysplasia (CINI), 3 of moderate dysplasia (CINII), and 6 of severe dysplasia (CINIII), or carcinoma-in-situ. </plain></SENT>
<SENT sid="98" pm="."><plain>The CIN tissues are positive for MUC16. </plain></SENT>
<SENT sid="99" pm="."><plain>Raw numbers of longSAGE tags generated and library names are given in Tables 1 and 2. </plain></SENT>
<SENT sid="100" pm="."><plain>DiscoverySpace (Robertson et al. </plain></SENT>
<SENT sid="101" pm="."><plain>2007), an in-house graphical software application backed by a relational database system designed to support SAGE gene expression analysis, was used to query data from over 25 publicly available data sources, as well as internal experimental results. </plain></SENT>
<SENT sid="102" pm="."><plain>Using DiscoverySpace, selected SAGE tag sequences were mapped to counterpart RefSeq (Pruitt et al. </plain></SENT>
<SENT sid="103" pm="."><plain>2000, 2005) genes and confirmed using SAGE tag co-ordinates to establish gene identity through Ensembl (Hubbard et al. </plain></SENT>
<SENT sid="104" pm="."><plain>2007; homo_sapiens_ core_41_36c). </plain></SENT>
<SENT sid="105" pm="."><plain>Genes were manually curated (EntrezGene) to ascertain gene identity and gene product localisation. </plain></SENT>
<SENT sid="106" pm="."><plain>These cervical longSAGE libraries were created from the epithelium of cervical biopsy samples collected just prior to LEEP (Loop Electrosurgical Excision Procedure). </plain></SENT>
<SENT sid="107" pm="."><plain>Tissue samples were placed into RNAIater and frozen at −80 °C within 10 minutes of being excised from the patient. </plain></SENT>
<SENT sid="108" pm="."><plain>These longSAGE libraries (Shadeo et al. </plain></SENT>
<SENT sid="109" pm="."><plain>2007) have been submitted to the NCBI Gene Expression Omnibus (GEO) repository. </plain></SENT>
</text></p><p><text><SENT sid="110" pm="."><plain>Any protein differentially expressed in cancer tissue, compared to normal tissue, or any protein known to be involved in cancer development, has potential as a candidate cancer biomarker. </plain></SENT>
<SENT sid="111" pm="."><plain>Genes presenting properties which identify them as likely targets for cancer diagnosis or prognosis must be separated from thousands of other genes which also may also possess clinical potential. </plain></SENT>
<SENT sid="112" pm="."><plain>Hundreds of potential candidates must be set aside in favour of gene products which offer the most promising characteristics. </plain></SENT>
<SENT sid="113" pm="."><plain>We focus on genes encoding membrane associated proteins because membrane-bound proteins are most likely to be accessible to topical application of contrast agents and have a rapid time frame for contrast agent visualization. </plain></SENT>
<SENT sid="114" pm="."><plain>Genes expressing the greatest number of tags combined with high levels of differential expression between dysplastic and normal tissue are the most likely to be observed by contrast agents in vivo. </plain></SENT>
</text></p><p><text><SENT sid="115" pm="."><plain>For optical imaging of tumors by topical application in vivo of contrast agents to be of practical use, a large number of contrast agent receptors are required. </plain></SENT>
<SENT sid="116" pm="."><plain>One of the standard methods to detect candidate biomarkers is to identify genes with amplified expression in cancer and/or normal tissues. </plain></SENT>
<SENT sid="117" pm="."><plain>We compared transcription profiles and retained the most highly expressed membrane-bound gene products whose differential expression level is greater than two-fold. </plain></SENT>
<SENT sid="118" pm="."><plain>Many cell-surface proteins can potentially be developed as targets for optical contrast agents. </plain></SENT>
<SENT sid="119" pm="."><plain>Using longSAGE, we have also identified the most highly differentially expressed transcripts between disease and normal tissue. Table 1 specifies those genes (with cell-surface gene products) up-regulated in the CINI and CINIII stages of dysplasia and Table 2 lists genes up-regulated in normal tissue. </plain></SENT>
<SENT sid="120" pm="."><plain>Short descriptions of these protein biomarkers are given in the appendix and annotations of protein structural information, if available, are included. </plain></SENT>
<SENT sid="121" pm="."><plain>Given that CINII is difficult to determine clinically, it was not included in these comparisons. </plain></SENT>
<SENT sid="122" pm="."><plain>Contrast agent visualization of the epidermal growth factor receptor (EGFR) using an anti-EGFR monoclonal antibody has already been successful (Rahman et al. </plain></SENT>
<SENT sid="123" pm="."><plain>2005). </plain></SENT>
<SENT sid="124" pm="."><plain>More of these markers should prove amenable to contrast agent development and topical formulations consisting of a range of contrast agents could help adjust to individual patient differences in gene expression. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="125" pm="."><plain>Cervical Intraepithelial Neoplasia Stage Biomarkers </plain></SENT>
</text></title><p><text><SENT sid="126" pm="."><plain>It is possible to evaluate a marker for presence or absence, but to correlate a marker or array of markers to changes in cellular localization relative to other markers is probably the most interesting and beneficial in terms of dysplasia progression, environment, therapy selection, and follow-up. </plain></SENT>
<SENT sid="127" pm="."><plain>The known function of these genes grants some insight into the biology of cervical neoplasia. </plain></SENT>
<SENT sid="128" pm="."><plain>For instance, several of these cell surface markers are involved in transport and/or signaling. </plain></SENT>
<SENT sid="129" pm="."><plain>MUCX and CD74, upregulated in CINI and CINIII, have signaling gene products known to be associated with carcinomas. </plain></SENT>
<SENT sid="130" pm="."><plain>CD74 is also known to be a high affinity binding protein for macrophage migration-inhibitory factor (MIF) which is implicated in tumor cell growth and angiogenesis. </plain></SENT>
<SENT sid="131" pm="."><plain>TSPAN1, upregulated in CINIII almost 10-fold, also plays a role in cell motility and growth. </plain></SENT>
<SENT sid="132" pm="."><plain>See Appendix for gene-specific references. </plain></SENT>
</text></p><p><text><SENT sid="133" pm="."><plain>Our analysis of cervical cancer longSAGE expression profiles direct attention to some genes with relatively equal distribution in CINI and CINIII, such as PIGR. </plain></SENT>
<SENT sid="134" pm="."><plain>Another marker, ANPEP, is present at significantly different expression levels in CINI and CINIII. </plain></SENT>
<SENT sid="135" pm="."><plain>This knowledge expands the possibilities for rapid visualization between normal and stages of dysplasia in vivo. </plain></SENT>
<SENT sid="136" pm="."><plain>As discussed earlier, these cell surface targets were found by identifying differentially expressed genes. </plain></SENT>
<SENT sid="137" pm="."><plain>More often than not, a highly expressed tag is not localised to the cell surface and, for these purposes, does not warrant further attention. </plain></SENT>
<SENT sid="138" pm="."><plain>However, a highly differentially expressed gene whose gene product is not membrane-bound is sometimes found to be part of a mechanism which affects the cell surface and thereby the gene product becomes of potential use. </plain></SENT>
<SENT sid="139" pm="."><plain>TFF3 (trefoil factor 3), for instance, is up-regulated 13-fold in CINIII and 27-fold in CINI. </plain></SENT>
<SENT sid="140" pm="."><plain>Members of the trefoil family are characterised by having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulphides. </plain></SENT>
<SENT sid="141" pm="."><plain>They are stable, secretory proteins whose functions are not defined but may protect the mucosa from insults, stabilize the mucus layer and affect healing of the epithelium. </plain></SENT>
<SENT sid="142" pm="."><plain>VANGL1 (Van Gogh-like protein 1) is an integral membrane protein which is serine/threonine phosphorylated and translocated to cytoplasmic vesicles in response to TFF3 stimulation (Kalabis et al. </plain></SENT>
<SENT sid="143" pm="."><plain>2006). </plain></SENT>
<SENT sid="144" pm="."><plain>VANGL1 protein acts as a downstream effector of TFF3 signalling and regulates wound healing of intestinal epithelium. </plain></SENT>
<SENT sid="145" pm="."><plain>TFF3 is commonly expressed in hepatocellular carcinoma and its expression correlates with tumor grade (Khoury et al. </plain></SENT>
<SENT sid="146" pm="."><plain>2005). </plain></SENT>
<SENT sid="147" pm="."><plain>TFF3 overexpression may be a critical process in mouse and human hepatocellular carcinogenesis (Okada et al. </plain></SENT>
<SENT sid="148" pm="."><plain>2005). </plain></SENT>
<SENT sid="149" pm="."><plain>The group of trefoil factor peptides (TFF1-3) are part of the protective mechanism operating in the intestinal mucosa and play a fundamental role in epithelial protection, repair, and restitution (Vieten et al. </plain></SENT>
<SENT sid="150" pm="."><plain>2005). </plain></SENT>
<SENT sid="151" pm="."><plain>TFF3 and the essential tumor angiogenesis regulator VEGF exert potent pro-invasive activity through STAT3 signalling in human colorectal cancer cells (Rivat et al. </plain></SENT>
<SENT sid="152" pm="."><plain>2005). </plain></SENT>
<SENT sid="153" pm="."><plain>That VANGL1 returned to cell membranes within 45 minutes of TFF3 stimulation (Kalabis et al. </plain></SENT>
<SENT sid="154" pm="."><plain>2006) could explain the low VANGL1 tag counts, 1–3 tags per library, observed in the longSAGE libraries. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec sec-type="conclusions"><title><text><SENT sid="155" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="156" pm="."><plain>Molecular specific contrast agents may provide the ability to directly image the cancer process; but biomarker discovery can be a lengthy process as candidate markers suitable for the task-at-hand must be identified from among thousands of proteins. </plain></SENT>
<SENT sid="157" pm="."><plain>SAGE-identified biomarkers hold promise for recognition of the stages of neoplasia by proteomic patterns. </plain></SENT>
<SENT sid="158" pm="."><plain>Optical contrast agents bound to these membrane-bound protein biomarkers will serve as a complement to histopathology, thus allowing more effective determination of tumor borders and non-invasive observation of response to treatment at a molecular level. </plain></SENT>
<SENT sid="159" pm="."><plain>We present fifty-six cell-surface gene products differentially expressed during progression of cervical intraepithelial neoplasia. </plain></SENT>
<SENT sid="160" pm="."><plain>Differential gene expression of these biomarkers will allow individualized selection of therapeutic combinations that best target the entire disease-protein system and advance understanding of carcinogenesis. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="161" pm="."><plain>This work was supported by a grant from the National Institutes of Health (NIH/NCI 1R01-CA103830-01) and by the British Columbia Cancer Foundation. </plain></SENT>
<SENT sid="162" pm="."><plain>MA Marra and SJM Jones are Scholars of the Michael Smith Foundation for Health Research and MA Marra is a Terry Fox Young Investigator of the National Cancer Institute of Canada. </plain></SENT>
<SENT sid="163" pm="."><plain>We also thank R Varhol, BCGSC, for tag mapping verficiation. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="APPENDIX"><app-group><app id="app1-bmi-2007-447"><title>Appendix</title><sec><title>Biomarker descriptions</title><p>ACTR3 ARP3 actin-related protein 3 homolog (yeast). The protein encoded by this gene is known to be a major constituent of the ARP2/3 complex (<xref ref-type="bibr" rid="b151-bmi-2007-447">Welch et al. 1997</xref>). This complex is located at the cell surface and is essential to cell shape and motility through lamellipodial actin assembly and protrusion (<xref ref-type="bibr" rid="b85-bmi-2007-447">Machesky et al. 1997</xref>).</p><p>Structure information: <underline>1K8K</underline> Crystal Structure of Arp2/3 Complex (<xref ref-type="bibr" rid="b121-bmi-2007-447">Robinson et al. 2001</xref>).</p><p><italic>ANPEP</italic> alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150). Human aminopeptidase N is a receptor for one strain of human coronavirus (<xref ref-type="bibr" rid="b160-bmi-2007-447">Yeager et al. 1992</xref>; <xref ref-type="bibr" rid="b16-bmi-2007-447">Breslin et al. 2003</xref>). The large extra-cellular carboxyterminal domain contains a pentapeptide consensus sequence characteristic of members of the zinc-binding metalloproteinase super-family. Defects in this gene appear to be a cause of various types of leukemia or lymphoma.</p><p><italic>BST2</italic> bone marrow stromal cell antigen 2. Bone marrow stromal cells are involved in the growth and development of B-cells and this protein may play a role in pre-B-cell growth (<xref ref-type="bibr" rid="b63-bmi-2007-447">Ishikawa et al. 1995</xref>).</p><p><italic>C3orf28</italic> chromosome 3 open reading frame 28 (HGTD-P). When overexpressed, HGTD-P induces cell death via mitochondrial apoptotic cascades (<xref ref-type="bibr" rid="b76-bmi-2007-447">Lee et al. 2004</xref>; <xref ref-type="bibr" rid="b71-bmi-2007-447">Kim et al. 2006</xref>).</p><p><italic>C14orf101</italic> chromosome 14 open reading frame 101. Integral to membrane (Ensembl-Gene ENSG00000070269: inferred from electronic annotation).</p><p><italic>CACNA2D3</italic> calcium channel, voltage-dependent, alpha 2/delta 3 subunit. This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex (<xref ref-type="bibr" rid="b51-bmi-2007-447">Hanke et al. 2001</xref>).</p><p><italic>CD74 CD74</italic> molecule, major histocompatibility complex MHC, class II invariant chain. CD74 is a nonpolymorphic type II integral membrane protein with an N-terminal cytoplasmic tail. CD74 is a regulated intra-membrane proteolysis RIP protein and its roles as a chaperone and as a signalling molecule are tightly regulated (<xref ref-type="bibr" rid="b139-bmi-2007-447">Stumptner-Cuvelette and Benaroch, 2002</xref>; <xref ref-type="bibr" rid="b10-bmi-2007-447">Becker-Herman et al. 2005</xref>). In addition, CD74 is an accessory signalling molecule during T-cell responses through interactions with CD44 (<xref ref-type="bibr" rid="b96-bmi-2007-447">Naujokas et al. 1993</xref>). Providing further evidence for its role in signal transduction pathways, CD74 is now known to be a high affinity binding protein for the proinflammatory cytokine, macrophage migration-inhibitory factor (MIF); MIF binds to the extracellular domain of CD74 (<xref ref-type="bibr" rid="b79-bmi-2007-447">Leng et al. 2003</xref>). MIF is also implicated in tumour cell growth and angiogenesis (<xref ref-type="bibr" rid="b97-bmi-2007-447">Nishihira, et al. 2003</xref>).</p><p>Structure information: <underline>1IIE</underline> (75 amino acids; 296 in CD74) HLA-DR antigens associated invariant chain (<xref ref-type="bibr" rid="b66-bmi-2007-447">Jasanoff et al. 1998</xref>). <underline>1MIF</underline> Macrophase migration inhibitory factor (MIF) (<xref ref-type="bibr" rid="b141-bmi-2007-447">Sun et al. 1996</xref>).</p><p><italic>CEACAM5</italic> carcinoembryonic antigen-related cell adhesion molecule 5. CEACAM1 interacts heterophilically with the CEA (CEACAM5) protein. Because CEA is expressed on a wide range of carcinomas and commonly used as tumour marker, a novel role for the CEA protein enabling the escape of tumour cells from NK-mediated killing is now apparent (<xref ref-type="bibr" rid="b138-bmi-2007-447">Stern et al. 2005</xref>).</p><p>Structure information: <underline>1E07</underline> Model of human carcinoembryonic antigen by homology modelling and curve-fitting to experimental solution scattering data (<xref ref-type="bibr" rid="b14-bmi-2007-447">Boehm and Perkins, 2000</xref>). <underline>2GK2</underline> Crystal structure of the N-terminal domain of human CEACAM1 (<xref ref-type="bibr" rid="b35-bmi-2007-447">Fedarovich et al. 2006</xref>). Using the BLOSUM62 comparison matrix, CEACAM1 (468 residues) has 74.3% identity to CEACAM5 (702 residues) in 412 residue overlap.</p><p><italic>CLCA4</italic> chloride channel, calcium activated, family member 4. The protein encoded by this gene belongs to the calcium sensitive chloride conductance protein family; the exact function is not known (<xref ref-type="bibr" rid="b2-bmi-2007-447">Agnel et al. 1999</xref>; <xref ref-type="bibr" rid="b118-bmi-2007-447">Ritzka et al. 2004</xref>).</p><p><italic>CLIC6</italic> chloride intracellular channel 6. This gene encodes a member of the chloride intracellular channel family of proteins.</p><p>Structure information: <underline>2D2Z</underline> Crystal structure of soluble form of CLIC4 (<xref ref-type="bibr" rid="b80-bmi-2007-447">Li et al. 2006</xref>).</p><p><italic>DSG1</italic> desmoglein 1. Desmoglein 1 is a calcium-binding trans-membrane glycoprotein component of desmosomes in vertebrate epithelial cells (<xref ref-type="bibr" rid="b153-bmi-2007-447">Wheeler et al. 1991</xref>; <xref ref-type="bibr" rid="b50-bmi-2007-447">Hanakawa et al. 2003</xref>).</p><p><italic>EMP1</italic> epithelial membrane protein 1. A well-known tumour-associated gene and a member of a novel family of genes encoding membrane glycoproteins (<xref ref-type="bibr" rid="b11-bmi-2007-447">Ben-Porath and Benvenisty, 1996</xref>; <xref ref-type="bibr" rid="b129-bmi-2007-447">Schiemann et al. 1997</xref>), EMP1 is a biomarker of gefitinib resistance (<xref ref-type="bibr" rid="b65-bmi-2007-447">Jain et al. 2005</xref>). Gefitinib is a small-molecule inhibitor that competes for the ATP-binding site on EGF receptor (EGFR) and has been approved for patients with advanced lung cancers.</p><p>Structure information: <underline>1EBP</underline> Complex between the extracellular domain of erythropoietin (EPO) receptor [EBP] and an agonist peptide [EMP1] (<xref ref-type="bibr" rid="b81-bmi-2007-447">Livnah et al. 1996</xref>).</p><p><italic>EPHA1</italic> EPH receptor A1. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system (<xref ref-type="bibr" rid="b37-bmi-2007-447">Flanagan and Vanderhaeghen, 1998</xref>). Structure information: <underline>2GSF</underline> The Human Epha3 Receptor Tyrosine Kinase and Juxtamembrane Region (<xref ref-type="bibr" rid="b23-bmi-2007-447">Davis et al. 2006</xref>). <underline>1MQB</underline> Crystal Structure of Ephrin A2 (ephA2) Receptor Protein Kinase (<xref ref-type="bibr" rid="b98-bmi-2007-447">Nowakowski et al. 2003</xref>).</p><p><italic>FADS2</italic> fatty acid desaturase 2. FADS family members are considered fusion products composed of an N-terminal cytochrome b5-like domain and a C-terminal multiple membrane-spanning desaturase portion, both of which are characterized by conserved histidine motifs (<xref ref-type="bibr" rid="b89-bmi-2007-447">Marquardt et al. 2000</xref>; <xref ref-type="bibr" rid="b128-bmi-2007-447">Schaeffer et al. 2006</xref>).</p><p><italic>FCGBP</italic> Fc fragment of IgG binding protein (<xref ref-type="bibr" rid="b73-bmi-2007-447">Kobayashi et al. 1991</xref>; <xref ref-type="bibr" rid="b53-bmi-2007-447">Harada et al. 1997</xref>; <xref ref-type="bibr" rid="b100-bmi-2007-447">O’Donovan et al. 2002</xref>). The encoded protein is made up of 3004 amino acid residues.</p><p><italic>FER1L4</italic> fer-1-like 4 (<italic>C. elegans</italic>). Novel human gene OTOF is the second member of a mammalian gene family related to <italic>C. elegans</italic> fer-1. It encodes a predicted cytosolic protein with a single carboxyterminal trans-membrane domain. The sequence homologies and predicted structure of otoferlin, the protein encoded by OTOF, suggest its involvement in vesicle membrane fusion (<xref ref-type="bibr" rid="b159-bmi-2007-447">Yasunaga et al. 1999</xref>).</p><p><italic>FGFR2</italic> fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome). FGFR2 is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform (<xref ref-type="bibr" rid="b7-bmi-2007-447">Bansal et al. 1997</xref>). The extra-cellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation.</p><p>Structure information: <underline>1OEC</underline> FGFR2 kinase domain (Ceska et al. 2004).</p><p><italic>FLJ32028</italic> transmembrane protein 154. Hypothetical protein LOC201799. Integral to membrane (Ensembl-Gene ENSG00000170006: inferred from electronic annotation).</p><p><italic>FXYD3</italic> FXYD domain containing ion transport regulator 3. FXYD2, also known as the gamma subunit of the Na,K-ATPase, regulates the properties of that enzyme. Trans-membrane topology has been established for two family members (FXYD1 and FXYD2), with the N-terminus extracellular and the C-terminus on the cytoplasmic side of the membrane (<xref ref-type="bibr" rid="b21-bmi-2007-447">Crowell et al. 2003</xref>; <xref ref-type="bibr" rid="b39-bmi-2007-447">Franzin et al. 2005</xref>). The protein encoded by this gene may function as a chloride channel or as a chloride channel regulator.</p><p><italic>GAS1</italic> growth arrest-specific 1. GAS1 plays a role in growth suppression and blocks entry to S phase and prevents cycling of normal and transformed cells (<xref ref-type="bibr" rid="b24-bmi-2007-447">Del Sal et al. 1992</xref>). Gas1 is a putative tumour suppressor gene (<xref ref-type="bibr" rid="b34-bmi-2007-447">Evdokiou and Cowled, 1998</xref>).</p><p><italic>GJB2</italic> gap junction protein, beta 2, 26kDa. The cytoplasmic domains of the connexion 26 gap junction surface, imaged at sub-molecular resolution, form a hexameric pore protruding from the membrane bilayer (<xref ref-type="bibr" rid="b92-bmi-2007-447">Muller et al. 2002</xref>).</p><p><italic>GPC4</italic> glypican 4. Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. These proteins may play a role in the control of cell division and growth regulation (<xref ref-type="bibr" rid="b12-bmi-2007-447">Bernfield et al. 1999</xref>).</p><p><italic>HLA-B</italic> major histocompatibility complex, class I, B. HLA-B belongs to the HLA class I heavy chain paralogues. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen and are expressed in nearly all cells. The heavy chain is anchored in the membrane.</p><p>Structure information: <underline>1HSA</underline> The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC (<xref ref-type="bibr" rid="b86-bmi-2007-447">Madden et al. 1992</xref>).</p><p><italic>HLA-DRA</italic> major histocompatibility complex, class II, DR alpha. It is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane, and it plays a central role in the immune system.</p><p>Structure information: <underline>1AQD</underline> HLA-DR1 (DRA, DRB1 0101) Human class II histocompatibility protein (extracellular domain) complexed with endogenous (<xref ref-type="bibr" rid="b93-bmi-2007-447">Murthy and Stern, 1997</xref>). <underline>1YMM</underline> TCR/HLA-DR2b/MBP-peptide complex (<xref ref-type="bibr" rid="b47-bmi-2007-447">Hahn et al. 2005</xref>).</p><p><italic>IL1R1</italic> interleukin 1 receptor, type I. This protein is a receptor for interleukin alpha, interleukin beta, and interleukin 1 receptor, type I (<xref ref-type="bibr" rid="b26-bmi-2007-447">Dower et al. 1986</xref>; <xref ref-type="bibr" rid="b91-bmi-2007-447">McMahan et al. 1991</xref>). It is an important mediator involved in many cytokine induced immune and inflammatory responses (<xref ref-type="bibr" rid="b13-bmi-2007-447">Boch et al. 2003</xref>). Structure information: <underline>1IRA</underline> Complex of the interleukin-1 receptor with the interleukin-1 receptor antagonist (IL1RA) (<xref ref-type="bibr" rid="b130-bmi-2007-447">Schreuder et al. 1997</xref>).</p><p><italic>ITR G</italic> protein-coupled receptor 180. This protein is produced predominantly in vascular smooth muscle cells and may play an important role in the regulation of vascular remodelling (<xref ref-type="bibr" rid="b62-bmi-2007-447">Iida et al. 2003</xref>).</p><p><italic>LOC644410</italic> FCGR1C Fc fragment of IgG, high affinity Ic, receptor (CD64). Only Fc gamma RI has high affinity for ligand and has a unique third extra-cellular domain (EC3). Three genes for human Fc gamma RI (A, B, and C) have been characterised; although they are remarkably similar, genes B and C are notably different from A (<xref ref-type="bibr" rid="b33-bmi-2007-447">Ernst et al. 1992</xref>).</p><p>Structure information: <underline>1E4J</underline> Crystal structure of the soluble human FC-gamma receptor III (<xref ref-type="bibr" rid="b137-bmi-2007-447">Sondermann et al. 2000</xref>).</p><p><italic>LY6E</italic> lymphocyte antigen 6 complex, locus E. Acute promyelocytic leukemia APL is a human malignancy that responds to differentiation therapy with all-trans-retinoic acid ATRA (<xref ref-type="bibr" rid="b58-bmi-2007-447">Huang et al. 1988</xref>). ATRA induces the expression of a novel human gene, RIG-E (<xref ref-type="bibr" rid="b88-bmi-2007-447">Mao et al. 1996</xref>). The amino acid composition of its product indicates that it is membrane-associated and has high homology to the murine LY-6 proteins and weak homology with a number of human growth factor receptors.</p><p><italic>MGC45438</italic> hypothetical protein MGC45438. Type I membrane protein (LOCATE).</p><p><italic>LYNX1</italic> Ly6/neurotoxin 1. Ly-6/neurotoxin gene family members are lymphocyte antigens that attach to the cell surface by a glycosylphosphatidylinositol anchor and have a unique structure displayed 8–10 conserved cysteine residues (<xref ref-type="bibr" rid="b144-bmi-2007-447">Tsuji et al. 2003</xref>). Functional analysis indicates that LYNX1 can enhance nicotinic acetylcholine receptor function in the presence of acetylcholine (<xref ref-type="bibr" rid="b4-bmi-2007-447">Arredondo et al. 2006</xref>). It is a new marker for human breast cancer (<xref ref-type="bibr" rid="b77-bmi-2007-447">Lee et al. 2006</xref>).</p><p><italic>LYPD3</italic> LY6/PLAUR domain containing 3 (C4.4A). This protein is known to be a structural homologue of the urokinase-type plasminogen activator receptor (uPAR) but little is known about its function (<xref ref-type="bibr" rid="b52-bmi-2007-447">Hansen et al. 2004</xref>).</p><p><italic>MAL</italic> mal, T-cell differentiation protein. The protein encoded by this gene is a highly hydrophobic integral membrane protein belonging to the MAL family of proteolipids (<xref ref-type="bibr" rid="b82-bmi-2007-447">Llorente et al. 2004</xref>; <xref ref-type="bibr" rid="b30-bmi-2007-447">Dukhovny et al. 2006</xref>).</p><p><italic>MUC1</italic> mucin 1, cell-surface associated. This gene is a member of the mucin family and encodes a membrane bound, glycosylated phosphoprotein. The protein is anchored to the apical surface of many epithelia by a trans-membrane domain, with the degree of glycosylation varying with cell type. The protein serves a protective function by binding to pathogens and also functions in a cell signalling capacity (<xref ref-type="bibr" rid="b115-bmi-2007-447">Ren et al. 2006</xref>). Over-expression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas (<xref ref-type="bibr" rid="b109-bmi-2007-447">Rabassa et al. 2006</xref>; <xref ref-type="bibr" rid="b110-bmi-2007-447">Raina et al. 2006</xref>).</p><p>Structure information: <underline>2ACM</underline> Solution structure of the SEA domain of human mucin 1 (MUC1) (<xref ref-type="bibr" rid="b84-bmi-2007-447">Macao et al. 2006</xref>).</p><p><italic>MUC16</italic> mucin 16 (CA125), cell surface associated. CA125 protein core is composed of a short cytoplasmic tail, a trans-membrane domain, and an extraordinarily large glycosylated extracellular structure. The extracellular domain encompasses an interactive disulfide bridged cysteine-loop and the site of OC125 and M11 binding (<xref ref-type="bibr" rid="b99-bmi-2007-447">O’Brien et al. 2001</xref>). It is known to be a marker in several cancers, including ovarian (<xref ref-type="bibr" rid="b163-bmi-2007-447">Yin et al. 2002</xref>), renal (<xref ref-type="bibr" rid="b6-bmi-2007-447">Bamias et al. 2003</xref>), and lung (<xref ref-type="bibr" rid="b106-bmi-2007-447">Pollan et al. 2003</xref>).</p><p><italic>NIP</italic> hypothetical protein FLJ32334 (DUOXA1). Multi-pass membrane protein (Ensembl-Gene ENSG00000140254: inferred from electronic annotation).</p><p><italic>ODZ2</italic> odz, odd Oz/ten-m homolog 2 (Drosophila). This protein is membrane-bound transcription regulator (Baqutti et al. 2003).</p><p><italic>PERP</italic> PERP, TP53 apoptosis effector. This tetraspan protein localizes to the plasma membrane, rather than to mitochondria, and may stimulate apoptosis (<xref ref-type="bibr" rid="b61-bmi-2007-447">Ihrie and Attardi, 2004</xref>).</p><p><italic>PIGR</italic> polymeric immunoglobulin receptor. PIGR mediates trans-cellular transport of polymeric immunoglobulin molecules. The receptor has 5 units with homology to the variable (V) units of immunoglobulins and a trans-membrane region, which also has some homology to certain immunoglobulin variable regions.</p><p>Structure information: <underline>1XED</underline> Crystal Structure of a Ligand-Binding Domain of the Human Polymeric Ig Receptor, pIgR (<xref ref-type="bibr" rid="b48-bmi-2007-447">Hamburger et al. 2004</xref>).</p><p><italic>PROM1</italic> prominin 1. The PROM1 gene codes for a pentaspan trans-membrane glycoprotein. The PROM1 antigen appears to belong to a new molecular family of 5-TM proteins which include an extra-cellular N-terminus, two short intracellular loops, two large extra-cellular loops and an intra-cellular C-terminus. PROM1 has been shown to be expressed on haemangioblasts and neural stem cells as well as on developing epithelium (<xref ref-type="bibr" rid="b57-bmi-2007-447">Horn et al. 1999</xref>; <xref ref-type="bibr" rid="b38-bmi-2007-447">Florek et al. 2005</xref>). No natural ligand has yet been demonstrated for the PROM1 molecule (<xref ref-type="bibr" rid="b158-bmi-2007-447">Wu et al. 2006</xref>).</p><p><italic>PSCA</italic> prostate stem cell antigen. This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein and a target for immunotherapy (<xref ref-type="bibr" rid="b114-bmi-2007-447">Reiter et al. 1998</xref>; <xref ref-type="bibr" rid="b152-bmi-2007-447">Wente et al. 2005</xref>).</p><p><italic>PTP4A2</italic> protein tyrosine phosphatase type IVA, member 2. The protein encoded by this gene belongs to a small class of prenylated protein tyrosine phosphatases (PTPs). PTPs are cell signalling molecules that play regulatory roles in a variety of cellular processes (<xref ref-type="bibr" rid="b8-bmi-2007-447">Bardelli et al. 2003</xref>; <xref ref-type="bibr" rid="b123-bmi-2007-447">Rouleau et al. 2006</xref>). Overexpression of this gene in mammalian cells conferred a transformed phenotype, which suggested its role in tumourigenesis (<xref ref-type="bibr" rid="b17-bmi-2007-447">Cates et al. 1996</xref>).</p><p>Structure information: <underline>1XM2</underline> Crystal structure of Human PRL-1 (<xref ref-type="bibr" rid="b67-bmi-2007-447">Jeong et al. 2005</xref>).</p><p><italic>PTP4A3</italic> protein tyrosine phosphatase type IVA, member 3. Over-expression of this PTP gene in mammalian cells was reported to inhibit angiotensin-II induced cell calcium mobilization and promote cell growth (<xref ref-type="bibr" rid="b90-bmi-2007-447">Matter et al. 2001</xref>).</p><p>Structure information: <italic>1V3A</italic> Structure of human PRL-3, the phosphatase associated with cancer metastasis (<xref ref-type="bibr" rid="b72-bmi-2007-447">Kim et al. 2004</xref>).</p><p><italic>PTPNS1</italic> SIRPA signal-regulatory protein alpha. Signal-regulatory-protein (SIRP) family members are receptor-type transmembrane glycoproteins known to be involved in the negative regulation of receptor tyrosine kinase-coupled signalling processes (<xref ref-type="bibr" rid="b69-bmi-2007-447">Kharitonenkov et al. 1997</xref>). CD47 has been known to be a ligand for this PTPNS1 (<xref ref-type="bibr" rid="b140-bmi-2007-447">Subramanian et al. 2006</xref>).</p><p>Structure information: <underline>2D9C</underline> Solution structure of the first ig-like domain of signal-regulatory protein beta-1 (SIRP-beta-1) (<xref ref-type="bibr" rid="b95-bmi-2007-447">Nagashima et al. 2005</xref>).</p><p><italic>RHCG</italic> Rh family, C glycoprotein. RhCG facilitates ammonium movement across the plasma membrane (<xref ref-type="bibr" rid="b165-bmi-2007-447">Zidi-Yahiaoui et al. 2005</xref>).</p><p><italic>SLC30A1</italic> solute carrier family 30 (zinc transporter), member 1. Transports zinc out of cells; its absence accounts for increased sensitivity of mutant cells to zinc toxicity (<xref ref-type="bibr" rid="b102-bmi-2007-447">Palmiter and Findley, 1995</xref>).</p><p><italic>SLC39A3</italic> solute carrier family 39 (zinc transporter), member 3. These eight-transmembrane domain proteins are part of the Zrt/Irt-like protein (ZIP) super-family of metal ion transporters and contain a conserved 12-amino acid signature sequence within the fourth transmembrane domain (<xref ref-type="bibr" rid="b41-bmi-2007-447">Gaither and Eide, 2000</xref>, <xref ref-type="bibr" rid="b42-bmi-2007-447">2001</xref>; <xref ref-type="bibr" rid="b29-bmi-2007-447">Dufner-Beattie et al. 2003</xref>).</p><p><italic>SRD5A2L</italic> steroid 5 alpha-reductase 2-like; 3-oxo-5-alpha-steroid 4 dehydrogenase activity.</p><p><italic>STRA6</italic> stimulated by retinoic acid gene 6 homolog (mouse). Stra6 codes for a very hydrophobic membrane protein of a new type, which does not display similarities with previously characterized integral membrane proteins (<xref ref-type="bibr" rid="b15-bmi-2007-447">Bouillet et al. 1997</xref>).</p><p><italic>TACSTD2</italic> tumour-associated calcium signal transducer 2. This gene encodes a carcinoma-associated antigen, defined by the monoclonal antibody GA733. TACSTD2 transduces an intra-cellular calcium signal and acts as a cell surface receptor (<xref ref-type="bibr" rid="b117-bmi-2007-447">Ripani et al. 1998</xref>).</p><p><italic>TFF3</italic> trefoil factor 3. Trefoil family members are stable, secretory proteins having at least one copy of the trefoil motif, a 40-amino acid domain that contains three conserved disulphides. VANGL, Van Gogh-like protein 1, is phosphorylated in response to Intestinal Trefoil Factor (ITF) stimulation. Vangl1 protein acts as a downstream effector of ITF/TFF3 signalling and regulates wound healing of the intestinal epithelium (<xref ref-type="bibr" rid="b68-bmi-2007-447">Kalabis et al. 2006</xref>). TFF3 is commonly expressed in hepatocellular carcinoma and its expression correlates with tumour grade (<xref ref-type="bibr" rid="b70-bmi-2007-447">Khoury et al. 2005</xref>).</p><p>Structure information: <underline>1E9T</underline> High resolution solution structure of human intestinal trefoil factor (<xref ref-type="bibr" rid="b78-bmi-2007-447">Lemercinier et al. 2001</xref>; <xref ref-type="bibr" rid="b94-bmi-2007-447">Muskett et al. 2003</xref>).</p><p><italic>TGFA</italic> transforming growth factor, alpha. TGF-alpha shows about 40% sequence homology with epidermal growth factor (EGF) and competes with EGF for binding to the EGF receptor (<xref ref-type="bibr" rid="b75-bmi-2007-447">Lee et al. 1985</xref>; <xref ref-type="bibr" rid="b155-bmi-2007-447">Winkler et al. 1989</xref>).</p><p>Structure information: <underline>1MOX</underline> Crystal Structure of Human Epidermal Growth Factor Receptor (residues 1-501) in complex with TGF-alpha (<xref ref-type="bibr" rid="b43-bmi-2007-447">Garret et al. 2002</xref>). <underline>2TGF</underline> The solution structure of human transforming growth factor alpha (Harvey et al. 2001).</p><p><italic>TMEM45B</italic> transmembrane protein 45B. Integral to membrane (Ensembl-Gene ENSG0000051715: inferred from electronic annotation).</p><p><italic>TMEM54</italic> transmembrane protein 54. Integral to membrane (Ensembl-Gene ENSG00000121900: inferred from electronic annotation).</p><p><italic>TMPRSS2</italic> transmembrane protease, serine 2. This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue (<xref ref-type="bibr" rid="b1-bmi-2007-447">Afar et al. 2001</xref>). The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage.</p><p>The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain.</p><p>Structure information: <underline>1Z8G</underline> Crystal structure of the extracellular region of the transmembrane serine protease hepsin with covalently bound preferred substrate (<xref ref-type="bibr" rid="b56-bmi-2007-447">Herter et al. 2005</xref>).</p><p><italic>TMPRSS11B</italic> transmembrane protease, serine 11B. Integral to membrane (Ensembl-Gene ENSG00000185873: inferred from electronic annotation).</p><p>Structure information: <underline>1Z8G</underline> (see TMPRSS2)</p><p><italic>TSPAN1</italic> tetraspanin 1. Most members of the trans-membrane 4 superfamily are cell-surface proteins characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility (<xref ref-type="bibr" rid="b143-bmi-2007-447">Todd et al. 1998</xref>). Tetraspanin protein, C4.8, identical to NET-1, has been implicated in cervical carcinogenesis (<xref ref-type="bibr" rid="b156-bmi-2007-447">Wollscheid et al. 2002</xref>).</p><p><italic>UPK1</italic><underline>A</underline> uroplakin 1A. The tetraspanin protein encoded by this gene is found in the asymmetrical unit membrane (AUM) where it can complex with other trans-membrane 4 superfamily proteins (<xref ref-type="bibr" rid="b164-bmi-2007-447">Yu et al. 1994</xref>). It may play a role in regulating membrane permeability of superficial umbrella cells or in stabilizing the apical membrane through AUM/cytoskeletal interactions (<xref ref-type="bibr" rid="b116-bmi-2007-447">Riedel et al. 2005</xref>).</p></sec></app></app-group></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="b1-bmi-2007-447"><text><SENT sid="164" pm="."><plain>AfarDEVivancoIHubertRS2001Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epitheliaCancer Res61416869211245484 </plain></SENT>
</text></ref><ref id="b2-bmi-2007-447"><text><SENT sid="165" pm="."><plain>AgnelMVermatTCulouscouJM1999Identification of three novel members of the calcium-dependent chloride channel (CaCC) family predominantly expressed in the digestive tract and tracheaFEBS Lett455329530110437792 </plain></SENT>
</text></ref><ref id="b3-bmi-2007-447"><text><SENT sid="166" pm="."><plain>Andersson-EngelsSKlintebergCaSvanberK1997In vivo fluorescence imaging for tissue diagnosticsPhys Med Biol42815249172261 </plain></SENT>
</text></ref><ref id="b4-bmi-2007-447"><text><SENT sid="167" pm="."><plain>ArredondoJChernyavskyAIJolkovskyDL2006SLURP-2: A novel cholinergic signaling peptide in human mucocutaneous epitheliumJ Cell Physiol20812384516575903 </plain></SENT>
</text></ref><ref id="b5-bmi-2007-447"><text><SENT sid="168" pm="."><plain>BaguttiCForroGFerralliJ2003The intracellular domain of teneurin-2 has a nuclear function and represses zic-1-mediated transcriptionJ Cell Sci116Pt 1429576612783990 </plain></SENT>
</text></ref><ref id="b6-bmi-2007-447"><text><SENT sid="169" pm="."><plain>BamiasAChortiMDeliveliotisC2003Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinomaUrology6223687312893366 </plain></SENT>
</text></ref><ref id="b7-bmi-2007-447"><text><SENT sid="170" pm="."><plain>BansalGSCoxHCMarshS1997Expression of keratinocyte growth factor and its receptor in human breast cancerBr J Cancer75111567749184170 </plain></SENT>
</text></ref><ref id="b8-bmi-2007-447"><text><SENT sid="171" pm="."><plain>BardelliASahaSSagerJA2003PRL-3 expression in metastatic cancersClin Cancer Res91556071514654542 </plain></SENT>
</text></ref><ref id="b9-bmi-2007-447"><text><SENT sid="172" pm="."><plain>BaselgaJGianniLGeyerC2004Future options with trastuzumab for primary systemic and adjuvant therapy. </plain></SENT>
<SENT sid="173" pm="."><plain>SeminOncol31517 </plain></SENT>
</text></ref><ref id="b10-bmi-2007-447"><text><SENT sid="174" pm="."><plain>Becker-HermanSArieGMedvedovskyH2005CD74 Is a Member of the Regulated Intramembrane Proteolysis-processed Protein FamilyMolecular Biology of the Cell1650616916107560 </plain></SENT>
</text></ref><ref id="b11-bmi-2007-447"><text><SENT sid="175" pm="."><plain>Ben-PorathIBenvenistyN1996Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteinsGene1831–269758996089 </plain></SENT>
</text></ref><ref id="b12-bmi-2007-447"><text><SENT sid="176" pm="."><plain>BernfieldMGotteMParkPW1999Functions of cell surface heparan sulfate proteoglycansAnnu Rev Biochem687297710872465 </plain></SENT>
</text></ref><ref id="b13-bmi-2007-447"><text><SENT sid="177" pm="."><plain>BochJAYoshidaYKoyamaY2003Characterization of a cascade of protein interactions initiated at the IL-1 receptorBiochem Biophys Res Commun30325253112659850 </plain></SENT>
</text></ref><ref id="b14-bmi-2007-447"><text><SENT sid="178" pm="."><plain>BoehmMKPerkinsSJ2000Structural Models for Carcinoembryonic Antigen and its Complex with the Single-Chain Fv Antibody Molecule Mfe23FEBS Lett4751110854848 </plain></SENT>
</text></ref><ref id="b15-bmi-2007-447"><text><SENT sid="179" pm="."><plain>BouilletPSapinVChazaudC1997Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane proteinMech Dev632173869203140 </plain></SENT>
</text></ref><ref id="b16-bmi-2007-447"><text><SENT sid="180" pm="."><plain>BreslinJJMorkISmithMK2003Human coronavirus 229E: receptor binding domain and neutralization by soluble receptor at 37 degrees CJ Virol7774435812634402 </plain></SENT>
</text></ref><ref id="b17-bmi-2007-447"><text><SENT sid="181" pm="."><plain>CatesCAMichaelRLStayrookKR1996Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatasesCancer Lett1101–249559018080 </plain></SENT>
</text></ref><ref id="b18-bmi-2007-447"><text><SENT sid="182" pm="."><plain>ChangHYSneddonJBAlizadehAA2004Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and woundsPloS Biol2220614 </plain></SENT>
</text></ref><ref id="b19-bmi-2007-447"><text><SENT sid="183" pm="."><plain>ChenYMillerCMosherR2003Identification of cervical cancer markers by cDNA and tissue microarraysCancer Res6319273512702585 </plain></SENT>
</text></ref><ref id="b20-bmi-2007-447"><text><SENT sid="184" pm="."><plain>CollierTLacyARichards-KortumR2002Near real-time confocal microscopy of amelanotic tissue: detection of dysplasia in ex vivo cervical tissueAcad Radiol95041212458875 </plain></SENT>
</text></ref><ref id="b21-bmi-2007-447"><text><SENT sid="185" pm="."><plain>CrowellKJFranzinCMKoltayA2003Expression and characterization of the FXYD ion transport regulators for NMR structural studies in lipid micelles and lipid bilayersBiochim Biophys Acta16451152112535606 </plain></SENT>
</text></ref><ref id="b22-bmi-2007-447"><text><SENT sid="186" pm="."><plain>CeskaTAOwensRDoyleCThe crystal structure of the Fgfr2 tyrosine kinase domain in complex with 4-aryl-2-phenylamino pyrimidine angiogenesis inhibitorsTo be Published </plain></SENT>
</text></ref><ref id="b23-bmi-2007-447"><text><SENT sid="187" pm="."><plain>DavisTWalkerJRDongA2006Structure of the human Epha3 receptor tyrosine kinase and juxtamembrane regionTo be Published </plain></SENT>
</text></ref><ref id="b24-bmi-2007-447"><text><SENT sid="188" pm="."><plain>Del SalGRuaroMEPhilipsonL1992The growth arrest-specific gene, gas1, is involved in growth suppressionCell7045956071505026 </plain></SENT>
</text></ref><ref id="b25-bmi-2007-447"><text><SENT sid="189" pm="."><plain>DoorbarJ2006Molecular biology of human papillomavirus infection and cervical cancerClin Sci (Lond)1105254116597322 </plain></SENT>
</text></ref><ref id="b26-bmi-2007-447"><text><SENT sid="190" pm="."><plain>DowerSKKronheimSRHoppTP1986The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identicalNature324609426682946959 </plain></SENT>
</text></ref><ref id="b27-bmi-2007-447"><text><SENT sid="191" pm="."><plain>DrukerBJ2004Imatinib as a paradigm of targeted therapiesAdv Cancer Res9113015327887 </plain></SENT>
</text></ref><ref id="b28-bmi-2007-447"><text><SENT sid="192" pm="."><plain>DuffyCLPhillipsSLKlingelhutzAJ2003Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6Virology31419620514517073 </plain></SENT>
</text></ref><ref id="b29-bmi-2007-447"><text><SENT sid="193" pm="."><plain>Dufner-BeattieJLangmadeSJWangF2003Structure, function, and regulation of a subfamily of mouse zinc transporter genesJ Biol Chem27850501425014525987 </plain></SENT>
</text></ref><ref id="b30-bmi-2007-447"><text><SENT sid="194" pm="."><plain>DukhovnyAGoldstein MagalLHirschbergK2006The MAL proteolipid restricts detergent-mediated membrane pore expansion and percolationMol Membr Biol2332455716785208 </plain></SENT>
</text></ref><ref id="b31-bmi-2007-447"><text><SENT sid="195" pm="."><plain>Entrez Gene2007URL: <ext-link ext-link-type="uri" xlink:href="www.ncbinlm.nih.gov/entrez/query.fcgi?db=gene">www.ncbinlm.nih.gov/entrez/query.fcgi?db=gene</ext-link> </plain></SENT>
</text></ref><ref id="b32-bmi-2007-447"><text><SENT sid="196" pm="."><plain>Entrez GEOURL: <ext-link ext-link-type="uri" xlink:href="www.ncbinlm.nih.gov/entrez/query.fcgi?db=geo">www.ncbinlm.nih.gov/entrez/query.fcgi?db=geo</ext-link> </plain></SENT>
</text></ref><ref id="b33-bmi-2007-447"><text><SENT sid="197" pm="."><plain>ErnstLKvan de WinkelJGChiuIM1992Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription productsJ Biol Chem26722156927001379234 </plain></SENT>
</text></ref><ref id="b34-bmi-2007-447"><text><SENT sid="198" pm="."><plain>EvdokiouACowledPA1998Tumor-suppressive activity of the growth arrest-specific gene GAS1 in human tumor cell linesInt J Cancer754568779466658 </plain></SENT>
</text></ref><ref id="b35-bmi-2007-447"><text><SENT sid="199" pm="."><plain>FedarovichATombergJNicholasRA2006Structure of the N-terminal domain of human CEACAM1: binding target of the opacity proteins during invasion of Neisseria meningitidis and N. gonorrhoeaeActa Crystallogr, Sect D62971916929097 </plain></SENT>
</text></ref><ref id="b36-bmi-2007-447"><text><SENT sid="200" pm="."><plain>FerrisDGLawheadRADickmanED2001Multimodal hyper-spectral imaging for the noninvasive diagnosis of cervical neoplasiaJ Low Genital Tract Dis526572 </plain></SENT>
</text></ref><ref id="b37-bmi-2007-447"><text><SENT sid="201" pm="."><plain>FlanaganJGVanderhaeghenP1998The ephrins and Eph receptors in neural developmentAnnu Rev Neurosci2130945Review9530499 </plain></SENT>
</text></ref><ref id="b38-bmi-2007-447"><text><SENT sid="202" pm="."><plain>FlorekMHaaseMMarzescoAM2005Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancerCell Tissue Res3191152615558321 </plain></SENT>
</text></ref><ref id="b39-bmi-2007-447"><text><SENT sid="203" pm="."><plain>FranzinCMYuJThaiK2005Correlation of gene and protein structures in the FXYD family proteinsJ Mol Biol35447435016288923 </plain></SENT>
</text></ref><ref id="b40-bmi-2007-447"><text><SENT sid="204" pm="."><plain>FraterJLTallmanMSVariakojisD2003Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec) Bone marrow histopathology and correlation with genetic statusAmerican Journal of Clinical Pathology11968334112817431 </plain></SENT>
</text></ref><ref id="b41-bmi-2007-447"><text><SENT sid="205" pm="."><plain>GaitherLAEideDJ2000Functional expression of the human hZIP2 zinc transporterJ Biol Chem27555606410681536 </plain></SENT>
</text></ref><ref id="b42-bmi-2007-447"><text><SENT sid="206" pm="."><plain>GaitherLAEideDJ2001The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cellsJ Biol Chem276222586411301334 </plain></SENT>
</text></ref><ref id="b43-bmi-2007-447"><text><SENT sid="207" pm="."><plain>GarrettTPJMcKernNMLouM2002Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alphaCell1107637312297049 </plain></SENT>
</text></ref><ref id="b44-bmi-2007-447"><text><SENT sid="208" pm="."><plain>GillenwaterAJacobRRichards-KortumR1998Fluorescence spectroscopy: a technique with potential to improve the early detection of aerodigestive tract neoplasiaHead Neck20556629702544 </plain></SENT>
</text></ref><ref id="b45-bmi-2007-447"><text><SENT sid="209" pm="."><plain>GonzálezSWhiteWMRajadhyakshaM1999Confocal imaging of sebaceous gland hyperplasia in vivo to assess efficacy and mechanism of pulsed dye laser treatmentLasers in Surgery and Medicine2581210421881 </plain></SENT>
</text></ref><ref id="b46-bmi-2007-447"><text><SENT sid="210" pm="."><plain>GurjarRSBackmanVPerelmanLT2001Imaging human epithelial properties with polarized light-scattering spectroscopyNat Med7111245811689891 </plain></SENT>
</text></ref><ref id="b47-bmi-2007-447"><text><SENT sid="211" pm="."><plain>HahnMNicholsonMJPyrdolJ2005Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptorNat Immunol64909615821740 </plain></SENT>
</text></ref><ref id="b48-bmi-2007-447"><text><SENT sid="212" pm="."><plain>HamburgerAEWestAPJrBjorkmanPJ2004Crystal structure of a polymeric immunoglobulin binding fragment of the human polymeric immunoglobulin receptorStructure1219253515530357 </plain></SENT>
</text></ref><ref id="b49-bmi-2007-447"><text><SENT sid="213" pm="."><plain>HanahanDWeinburgRA2000The hallmarks of cancerCell100577010647931 </plain></SENT>
</text></ref><ref id="b50-bmi-2007-447"><text><SENT sid="214" pm="."><plain>HanakawaYSelwoodTWooD2003Calcium-dependent conformation of desmoglein 1 is required for its cleavage by exfoliative toxinJ Invest Dermatol1212383912880431 </plain></SENT>
</text></ref><ref id="b51-bmi-2007-447"><text><SENT sid="215" pm="."><plain>HankeSBugertPChudekJ2001Cloning a calcium channel alpha2delta-3 subunit gene from a putative tumor suppressor gene region at chromosome 3p21.1 in conventional renal cell carcinomaGene2641697511245980 </plain></SENT>
</text></ref><ref id="b52-bmi-2007-447"><text><SENT sid="216" pm="."><plain>HansenLVGardsvollHNielsenBS2004Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptorBiochem J380Pt 38455715012588 </plain></SENT>
</text></ref><ref id="b53-bmi-2007-447"><text><SENT sid="217" pm="."><plain>HaradaNIijimaSKobayashiK1997Human IgGFc binding protein (FcgammaBP) in colonic epithelial cells exhibits mucin-like structureJ Biol Chem2722415232419182547 </plain></SENT>
</text></ref><ref id="b54-bmi-2007-447"><text><SENT sid="218" pm="."><plain>HarisinghaniMGBarentszJHahnPF2003Non-invasive detection of clinically occult lymph-node metastases in prostate cancerN Engl J Med34824919912815134 </plain></SENT>
</text></ref><ref id="b55-bmi-2007-447"><text><SENT sid="219" pm="."><plain>HarveyTSWilkinsonAJTappinMJ1991The solution structure of human transforming growth factor alphaEur J Biochem198555622050136 </plain></SENT>
</text></ref><ref id="b56-bmi-2007-447"><text><SENT sid="220" pm="."><plain>HerterSPiperDEAaronW2005Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancersBiochem J3901253615839837 </plain></SENT>
</text></ref><ref id="b57-bmi-2007-447"><text><SENT sid="221" pm="."><plain>HornPATeschHStaibP1999Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cellsBlood9341435710075457 </plain></SENT>
</text></ref><ref id="b58-bmi-2007-447"><text><SENT sid="222" pm="."><plain>HuangMEYeYCChenSR1988Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood722567723165295 </plain></SENT>
</text></ref><ref id="b59-bmi-2007-447"><text><SENT sid="223" pm="."><plain>HubbardTJPAkenBLBealK2006Ensembl 2007Nuc Acids Res00Database issue D18 </plain></SENT>
</text></ref><ref id="b60-bmi-2007-447"><text><SENT sid="224" pm="."><plain>HuzairaMRiusFRajadhyakshaM2001Topographic variations in normal skin, as viewed by in vivo reflectance confocal microscopyThe Journal of Investigative Dermatology1168465211407970 </plain></SENT>
</text></ref><ref id="b61-bmi-2007-447"><text><SENT sid="225" pm="."><plain>IhrieRAAttardiLD2004Perpetrating p53-dependent apoptosisCell Cycle33267914726658 </plain></SENT>
</text></ref><ref id="b62-bmi-2007-447"><text><SENT sid="226" pm="."><plain>IidaATanakaTNakamuraY2003High-density SNP map of human ITR, a gene associated with vascular remodelingJ Hum Genet484170212730718 </plain></SENT>
</text></ref><ref id="b63-bmi-2007-447"><text><SENT sid="227" pm="."><plain>IshikawaJKaishoTTomizawaH1995Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growthGenomics263527347607676 </plain></SENT>
</text></ref><ref id="b64-bmi-2007-447"><text><SENT sid="228" pm="."><plain>JafferFAWeisslederR2005Molecular imaging in the clinical arenaJAMA29378556215713776 </plain></SENT>
</text></ref><ref id="b65-bmi-2007-447"><text><SENT sid="229" pm="."><plain>JainATindellCALauxI2005Proc Natl Acad Sci USA10233118586316087880 </plain></SENT>
</text></ref><ref id="b66-bmi-2007-447"><text><SENT sid="230" pm="."><plain>JasanoffAWagnerGWileyDC1998Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein IiEMBO J176812189843486 </plain></SENT>
</text></ref><ref id="b67-bmi-2007-447"><text><SENT sid="231" pm="."><plain>JeongDGKimSJKimJH2005Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanismsJ Mol Biol3454011315571731 </plain></SENT>
</text></ref><ref id="b68-bmi-2007-447"><text><SENT sid="232" pm="."><plain>KalabisJRosenbergIPodolskyDK2006Vangl1 protein acts as a downstream effector of intestinal trefoil factor (ITF)/TFF3 signaling and regulates wound healing of intestinal epitheliumJ Biol Chem2811064344116410243 </plain></SENT>
</text></ref><ref id="b69-bmi-2007-447"><text><SENT sid="233" pm="."><plain>KharitonenkovAChenZSuresI1997A family of proteins that inhibit signalling through tyrosine kinase receptorsNature386662118169062191 </plain></SENT>
</text></ref><ref id="b70-bmi-2007-447"><text><SENT sid="234" pm="."><plain>KhouryTChadhaKJavleM2005Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinomaInt J Gastrointest Cancer353171716110118 </plain></SENT>
</text></ref><ref id="b71-bmi-2007-447"><text><SENT sid="235" pm="."><plain>KimJYKimSMKoJH2006Interaction of pro-apoptotic protein HGTD-P with heat shock protein 90 is required for induction of mitochondrial apoptotic cascadesFEBS Lett580133270516698020 </plain></SENT>
</text></ref><ref id="b72-bmi-2007-447"><text><SENT sid="236" pm="."><plain>KimKASongJSJeeJ2004Structure of human PRL-3, the phosphatase associated with cancer metastasisFebs Lett565181715135076 </plain></SENT>
</text></ref><ref id="b73-bmi-2007-447"><text><SENT sid="237" pm="."><plain>KobayashiKHamadaYBlaserMJ1991The molecular configuration and ultrastructural locations of an IgG Fc binding site in human colonic epitheliumJ Immunol146168741984453 </plain></SENT>
</text></ref><ref id="b74-bmi-2007-447"><text><SENT sid="238" pm="."><plain>LangleyRGRajadhyakshaMDwyerPJ2001Confocal scanning laser microscopy of benign and malignant melanocytic skin lesions in vivoJournal of the American Academy of Dermatology453657611511832 </plain></SENT>
</text></ref><ref id="b75-bmi-2007-447"><text><SENT sid="239" pm="."><plain>LeeDCRoseTMWebbNR1985Cloning and sequence analysis of a cDNA for rat transforming growth factor-alphaNature3136002489913855503 </plain></SENT>
</text></ref><ref id="b76-bmi-2007-447"><text><SENT sid="240" pm="."><plain>LeeMJKimJYSukK2004Identification of the hypoxia-inducible factor 1 alpha-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathwayMol Cell Biol24939182715082785 </plain></SENT>
</text></ref><ref id="b77-bmi-2007-447"><text><SENT sid="241" pm="."><plain>LeeJWLeeYSYooKH2006LY-6K gene: a novel molecular marker for human breast cancerOncol Rep1661211417089039 </plain></SENT>
</text></ref><ref id="b78-bmi-2007-447"><text><SENT sid="242" pm="."><plain>LemercinierXMuskettFWCheesemanB2001High-resolution solution structure of human intestinal trefoil factor and functional insights from detailed structural comparisons with the other members of the trefoil family of mammalian cell motility factorsBiochemistry4095525911583154 </plain></SENT>
</text></ref><ref id="b79-bmi-2007-447"><text><SENT sid="243" pm="."><plain>LengLMetzCNFangY2003MIF signal transduction initiated by binding to CD74J Exp Med19714677612782713 </plain></SENT>
</text></ref><ref id="b80-bmi-2007-447"><text><SENT sid="244" pm="."><plain>LiYFLiDFZengZH2006Trimeric structure of the wild soluble chloride intracellular ion channel CLIC4 observed in crystalsBiochem Biophys Res Commun34312727816581025 </plain></SENT>
</text></ref><ref id="b81-bmi-2007-447"><text><SENT sid="245" pm="."><plain>LivnahOSturaEAJohnsonDL1996Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 ÅScience273464718662530 </plain></SENT>
</text></ref><ref id="b82-bmi-2007-447"><text><SENT sid="246" pm="."><plain>LlorenteAde MarcoMCAlonsoMA2004Caveolin-1 and MAL are located on prostasomes secreted by the prostate cancer PC-3 cell lineJ Cell Sci117Pt 2253435115466889 </plain></SENT>
</text></ref><ref id="b83-bmi-2007-447"><text><SENT sid="247" pm="."><plain>LOCATE. subcellular localization database. </plain></SENT>
<SENT sid="248" pm="."><plain>Copyright 2004, 2005, Institute of Molecular Bioscience, University of Queensland and the ARC Centre in Bioinformatics. </plain></SENT>
</text></ref><ref id="b84-bmi-2007-447"><text><SENT sid="249" pm="."><plain>MacaoBJohanssonDGAHanssonGC2006Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucinNat Struct Mol Biol1371616369486 </plain></SENT>
</text></ref><ref id="b85-bmi-2007-447"><text><SENT sid="250" pm="."><plain>MacheskyLMReevesEWientjesF1997Mammalian actin-related protein 2/3 complex localizes to regions of lamellipodial protrusion and is composed of evolutionarily conserved proteinsBiochem J328Pt 1105129359840 </plain></SENT>
</text></ref><ref id="b86-bmi-2007-447"><text><SENT sid="251" pm="."><plain>MaddenDRGorgaJCStromingerJL1992The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHCCell701035481525820 </plain></SENT>
</text></ref><ref id="b87-bmi-2007-447"><text><SENT sid="252" pm="."><plain>MaddenSLWangCJLandesG2000Serial analysis of gene expression: from gene discovery to target identificationDrug Discovery Today594152510931659 </plain></SENT>
</text></ref><ref id="b88-bmi-2007-447"><text><SENT sid="253" pm="."><plain>MaoMYuMTongJH1996RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cellPNAS935910148650192 </plain></SENT>
</text></ref><ref id="b89-bmi-2007-447"><text><SENT sid="254" pm="."><plain>MarquardtAStohrHWhiteK2000cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase familyGenomics6621758310860662 </plain></SENT>
</text></ref><ref id="b90-bmi-2007-447"><text><SENT sid="255" pm="."><plain>MatterWFEstridgeTZhangC2001Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signalingBiochem Biophys Res Commun28351061811355880 </plain></SENT>
</text></ref><ref id="b91-bmi-2007-447"><text><SENT sid="256" pm="."><plain>McMahanCJSlackJLMosleyB1991A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell typesEMBO J10102821321833184 </plain></SENT>
</text></ref><ref id="b92-bmi-2007-447"><text><SENT sid="257" pm="."><plain>MullerDJHandGMEngelA2002Conformational changes in surface structures of isolated connexin 26 gap junctionsEMBO J2114359860712110573 </plain></SENT>
</text></ref><ref id="b93-bmi-2007-447"><text><SENT sid="258" pm="."><plain>MurthyVLSternLJ1997The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide bindingStructure51385969351812 </plain></SENT>
</text></ref><ref id="b94-bmi-2007-447"><text><SENT sid="259" pm="."><plain>MuskettFWMayFEWestleyBR2003Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteinsBiochemistry4251151394714690424 </plain></SENT>
</text></ref><ref id="b95-bmi-2007-447"><text><SENT sid="260" pm="."><plain>NagashimaKHayashiFYoshidaM2005Solution structure of the first ig-like domain of signal-regulatory protein beta-1 (SIRP-beta-1)To be Published </plain></SENT>
</text></ref><ref id="b96-bmi-2007-447"><text><SENT sid="261" pm="."><plain>NaujokasMFMorinMAndersonMS1993The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44Cell74257688343954 </plain></SENT>
</text></ref><ref id="b97-bmi-2007-447"><text><SENT sid="262" pm="."><plain>NishihiraJIshibashiTFukushimaT2003Macrophage migration inhibitory factor (MIF): its potential role in tumor growth and tumor-associated angiogenesisAnn NY Acad Sci9951718212814949 </plain></SENT>
</text></ref><ref id="b98-bmi-2007-447"><text><SENT sid="263" pm="."><plain>NowakowskiJCroninCNMcReeDE2003Structures of the cancer related Aurora-A, FAK and EphA2 protein kinases from nanovolume crystallographyStructure1016596712467573 </plain></SENT>
</text></ref><ref id="b99-bmi-2007-447"><text><SENT sid="264" pm="."><plain>O’BrienTJBeardJBUnderwoodLJ2001The CA 125 gene: an extracellular superstructure dominated by repeat sequencesTumour Biol2263486611786729 </plain></SENT>
</text></ref><ref id="b100-bmi-2007-447"><text><SENT sid="265" pm="."><plain>O’DonovanNFischerAAbdoEM2002Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomasJ Endocrinol17435172412208673 </plain></SENT>
</text></ref><ref id="b101-bmi-2007-447"><text><SENT sid="266" pm="."><plain>OkadaHKimuraMTTanD2005Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomasInt J Oncol2623697715645121 </plain></SENT>
</text></ref><ref id="b102-bmi-2007-447"><text><SENT sid="267" pm="."><plain>PalmiterRDFindleySD1995Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zincEMBO J144639497882967 </plain></SENT>
</text></ref><ref id="b103-bmi-2007-447"><text><SENT sid="268" pm="."><plain>PapanicolaouGNTrautHF1943Diagnosis of Uterine Cancer by the Vaginal Smear. </plain></SENT>
<SENT sid="269" pm="."><plain>New York: The Commonwealth Fund. </plain></SENT>
<SENT sid="270" pm="."><plain>1997. </plain></SENT>
<SENT sid="271" pm="."><plain>The diagnostic value of vaginal smears in carcinoma of the uterus, 1941. </plain></SENT>
<SENT sid="272" pm="."><plain>1997Arch Pathol Lab Med1213211249111103 </plain></SENT>
</text></ref><ref id="b104-bmi-2007-447"><text><SENT sid="273" pm="."><plain>Pérez-PlasenciaCRigginsGVázquez-OrtizG2005Characterization of the global profile of genes expressed in cervical epithelium by Serial Analysis of Gene Expression (SAGE)BMC Genomics6130816171524 </plain></SENT>
</text></ref><ref id="b105-bmi-2007-447"><text><SENT sid="274" pm="."><plain>PleasanceEDMarraMAJonesSJM2003Assessment of SAGE in transcript identificationGenome Res1312031512743019 </plain></SENT>
</text></ref><ref id="b106-bmi-2007-447"><text><SENT sid="275" pm="."><plain>PollanMVarelaGTorresA2003Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancerInt J Cancer10757819014566828 </plain></SENT>
</text></ref><ref id="b107-bmi-2007-447"><text><SENT sid="276" pm="."><plain>PruittKDKatzKSSicotteH2000Introducing RefSeq and LocusLink: curated human genome resources at the NCBITrends Genet16144710637631 </plain></SENT>
</text></ref><ref id="b108-bmi-2007-447"><text><SENT sid="277" pm="."><plain>PruittKDTatusovaTMaglottDR2005NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteinsNucleic Acids Res331D501D50415608248 </plain></SENT>
</text></ref><ref id="b109-bmi-2007-447"><text><SENT sid="278" pm="."><plain>RabassaMECroceMVPereyraA2006MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysisBMC Cancer625317064405 </plain></SENT>
</text></ref><ref id="b110-bmi-2007-447"><text><SENT sid="279" pm="."><plain>RainaDAhmadRKumarS2006MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damageEMBO J251637748316888623 </plain></SENT>
</text></ref><ref id="b111-bmi-2007-447"><text><SENT sid="280" pm="."><plain>RahmanMAbd-El-BarrMMackV2005Optical imaging of cervical pre-cancers with structured illumination: An integrated approachGynecologic Oncology99S112S11516154624 </plain></SENT>
</text></ref><ref id="b112-bmi-2007-447"><text><SENT sid="281" pm="."><plain>RajadhyakshaMAndersonRRWebbRH1999Video-rate confocal scanning laser microscope for imaging human tissues in vivoApplied Optics3821051518319771 </plain></SENT>
</text></ref><ref id="b113-bmi-2007-447"><text><SENT sid="282" pm="."><plain>RamanujamN2000Fluorescence spectroscopy of neoplastic and non-neoplastic tissuesNeoplasia21–28911710933071 </plain></SENT>
</text></ref><ref id="b114-bmi-2007-447"><text><SENT sid="283" pm="."><plain>ReiterREGuZWatabeT1998Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancerProc Natl Acad Sci USA9541735409465086 </plain></SENT>
</text></ref><ref id="b115-bmi-2007-447"><text><SENT sid="284" pm="."><plain>RenJRainaDChenW2006MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signalingMol Cancer Res4118738317114345 </plain></SENT>
</text></ref><ref id="b116-bmi-2007-447"><text><SENT sid="285" pm="."><plain>RiedelILiangFXDengFM2005Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?Eur J Cell Biol842–339340515819416 </plain></SENT>
</text></ref><ref id="b117-bmi-2007-447"><text><SENT sid="286" pm="."><plain>RipaniESacchettiACordaD1998Human Trop-2 is a tumor-associated calcium signal transducerInt J Cancer76567169610724 </plain></SENT>
</text></ref><ref id="b118-bmi-2007-447"><text><SENT sid="287" pm="."><plain>RitzkaMStankeFJansenS2004The CLCA gene locus as a modulator of the gastrointestinal basic defect in cystic fibrosisHum Genet11564839115490240 </plain></SENT>
</text></ref><ref id="b119-bmi-2007-447"><text><SENT sid="288" pm="."><plain>RivatCRodriguesSBruyneelE2005Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3)—and vascular endothelial growth factor-mediated cellular invasion and tumor growthCancer Res65119520215665295 </plain></SENT>
</text></ref><ref id="b120-bmi-2007-447"><text><SENT sid="289" pm="."><plain>RobertsonNOveisi-FordoreiMZuyderduynS2007DiscoverySpace: an interactive data analysis applicationGenome Biology8R617210078 </plain></SENT>
</text></ref><ref id="b121-bmi-2007-447"><text><SENT sid="290" pm="."><plain>RobinsonRCTurbedskyKKaiserDA2001Crystal structure of Arp2/3 complexScience29467984 </plain></SENT>
</text></ref><ref id="b122-bmi-2007-447"><text><SENT sid="291" pm="."><plain>RossJSFletcherJABloomKJ2004Targeted therapy in breast cancer: the HER-2/neu gene and proteinMol Cell Proteomics343799814762215 </plain></SENT>
</text></ref><ref id="b123-bmi-2007-447"><text><SENT sid="292" pm="."><plain>RouleauCRoyASt MartinT2006Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and functionMol Cancer Ther522192916505094 </plain></SENT>
</text></ref><ref id="b124-bmi-2007-447"><text><SENT sid="293" pm="."><plain>RudinMWeisslederR2003Molecular imaging in drug discovery and developmentNat Rev Drug Discov21233112563303 </plain></SENT>
</text></ref><ref id="b125-bmi-2007-447"><text><SENT sid="294" pm="."><plain>RuutuMPeitsaroPJohanssonB2002Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integrationInt J Cancer1003182612115547 </plain></SENT>
</text></ref><ref id="b126-bmi-2007-447"><text><SENT sid="295" pm="."><plain>SahaSSparksABRagoC2002Using the transcriptome to annotate the genomeNat Biotechnol205081211981567 </plain></SENT>
</text></ref><ref id="b127-bmi-2007-447"><text><SENT sid="296" pm="."><plain>SanderJNgRTSleumerMC2005A methodology for analyzing SAGE libraries for cancer profilingACM Transactions on Information Systems2313560 </plain></SENT>
</text></ref><ref id="b128-bmi-2007-447"><text><SENT sid="297" pm="."><plain>SchaefferLGohlkeHMullerM2006Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipidsHum Mol Genet151117455616670158 </plain></SENT>
</text></ref><ref id="b129-bmi-2007-447"><text><SENT sid="298" pm="."><plain>SchiemannSRuckelsMEngelholmLH1997Differential gene expression in human mammary carcinoma cells: identification of a new member of a receptor familyAnticancer Res171A13209066625 </plain></SENT>
</text></ref><ref id="b130-bmi-2007-447"><text><SENT sid="299" pm="."><plain>SchreuderHTardifCTrump-KallmeyerS1997A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonistNature3861942009062194 </plain></SENT>
</text></ref><ref id="b131-bmi-2007-447"><text><SENT sid="300" pm="."><plain>SelkinBRajadhyakshaMGonzálezS2001In vivo confocal microscopy in dermatologyDermatologic Clinics1923697711556245 </plain></SENT>
</text></ref><ref id="b132-bmi-2007-447"><text><SENT sid="301" pm="."><plain>ShadeoAChariRLonerganKMPusicAMillerDEhlenTVan NiekerkDMatisicJRichards-KortumRFollenMGuillaudMLamWLMacAulayC2007BMC GenomicsSubmitted September </plain></SENT>
</text></ref><ref id="b133-bmi-2007-447"><text><SENT sid="302" pm="."><plain>ShimCZhangWRheeCH1998Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression arrayClin Cancer Res43045509865919 </plain></SENT>
</text></ref><ref id="b134-bmi-2007-447"><text><SENT sid="303" pm="."><plain>SokolovKDrezekRGossageK1999Reflectance spectroscopy with polarized light: is it sensitive to cellular and nuclear morphology?Opt Express51330219401735 </plain></SENT>
</text></ref><ref id="b135-bmi-2007-447"><text><SENT sid="304" pm="."><plain>SokolovKFollenMRichards-KortumR2002Optical spectroscopy for detection of neoplasiaCurr Opin Chem Biol66515812413550 </plain></SENT>
</text></ref><ref id="b136-bmi-2007-447"><text><SENT sid="305" pm="."><plain>SokolovKAaronJHsuB2003Optical systems for in vivo molecular imaging of cancerTechnology in Cancer Research and Treatment2649150414640761 </plain></SENT>
</text></ref><ref id="b137-bmi-2007-447"><text><SENT sid="306" pm="."><plain>SondermannPHuberROosthuizenV2000The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complexNature4062677310917521 </plain></SENT>
</text></ref><ref id="b138-bmi-2007-447"><text><SENT sid="307" pm="."><plain>SternNMarkelGArnonTI2005Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1J Immunol17411669270115905509 </plain></SENT>
</text></ref><ref id="b139-bmi-2007-447"><text><SENT sid="308" pm="."><plain>Stumptner-CuvelettePBenarochP2002Multiple roles of the invariant chain in MHC class II functionBiochim Biophys Acta154211311853874 </plain></SENT>
</text></ref><ref id="b140-bmi-2007-447"><text><SENT sid="309" pm="."><plain>SubramanianSParthasarathyRSenS2006Species- and cell type-specific interactions between CD47 and human SIRPalphaBlood107625485616291597 </plain></SENT>
</text></ref><ref id="b141-bmi-2007-447"><text><SENT sid="310" pm="."><plain>SunHWBernhagenJBucalaR1996Crystal structure at 2.6-Å resolution of human macrophage migration inhibitory factorProc Natl Acad Sci USA935191968643551 </plain></SENT>
</text></ref><ref id="b142-bmi-2007-447"><text><SENT sid="311" pm="."><plain>ThomasJTOhSTTerhuneSS2001Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomesJ Virol7575647111462028 </plain></SENT>
</text></ref><ref id="b143-bmi-2007-447"><text><SENT sid="312" pm="."><plain>ToddSCDoctorVSLevyS1998Sequences and expression of six new members of the tetraspanin/TM4SF familyBiochim Biophys Acta1399110149714763 </plain></SENT>
</text></ref><ref id="b144-bmi-2007-447"><text><SENT sid="313" pm="."><plain>TsujiHOkamotoKMatsuzakaY2003SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgarisGenomics811263312573258 </plain></SENT>
</text></ref><ref id="b145-bmi-2007-447"><text><SENT sid="314" pm="."><plain>UtzingerUBrewerMSilvaE2001Reflectance spectroscopy for in vivo characterization of ovarian tissueLasers Surg Med28566611430444 </plain></SENT>
</text></ref><ref id="b146-bmi-2007-447"><text><SENT sid="315" pm="."><plain>VelculescuVEZhangLZhouW1997Characterization of the yeast transcriptomeCell882243519008165 </plain></SENT>
</text></ref><ref id="b147-bmi-2007-447"><text><SENT sid="316" pm="."><plain>VelculescuVEZhangLVogelsteinB1995Serial analysis of gene expressionScience27048477570003 </plain></SENT>
</text></ref><ref id="b148-bmi-2007-447"><text><SENT sid="317" pm="."><plain>VietenDCorfieldACarrollD2005Impaired mucosal regeneration in neonatal necrotising enterocolitisPediatr Surg Int2131536015578191 </plain></SENT>
</text></ref><ref id="b149-bmi-2007-447"><text><SENT sid="318" pm="."><plain>WagnièresGAStarWMWilsonBC1998In vivo fluorescence spectroscopy and imaging for oncological applicationsPhotochem Photobiol685603329825692 </plain></SENT>
</text></ref><ref id="b150-bmi-2007-447"><text><SENT sid="319" pm="."><plain>WeisslederR2002Scaling down imaging: molecular mapping of cancer in miceNat Rev Cancer2111811902581 </plain></SENT>
</text></ref><ref id="b151-bmi-2007-447"><text><SENT sid="320" pm="."><plain>WelchMDIwamatsuAMitchisonTJ1997Actin polymerization is induced by Arp2/3 protein complex at the surface of Listeria monocytogenesNature385661326599000076 </plain></SENT>
</text></ref><ref id="b152-bmi-2007-447"><text><SENT sid="321" pm="."><plain>WenteMNJainAKonoE2005Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancerPancreas3121192516024997 </plain></SENT>
</text></ref><ref id="b153-bmi-2007-447"><text><SENT sid="322" pm="."><plain>WheelerGNParkerAEThomasCL1991Desmosomal glycoprotein DGI, a component of intercellular desmosome junctions, is related to the cadherin family of cell adhesion moleculesProc Natl Acad Sci USA881147968001711210 </plain></SENT>
</text></ref><ref id="b154-bmi-2007-447"><text><SENT sid="323" pm="."><plain>WhiteWMRajadhyakshaMGonzálezS1999Noninvasive imaging of human oral mucosa in vivo by confocal reflectance microscopyLaryngoscope10917091710522947 </plain></SENT>
</text></ref><ref id="b155-bmi-2007-447"><text><SENT sid="324" pm="."><plain>WinklerMEO’ConnorLWingetM1989Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptorBiochemistry2815637382790004 </plain></SENT>
</text></ref><ref id="b156-bmi-2007-447"><text><SENT sid="325" pm="."><plain>WollscheidVKuhne-HeidRSteinI2002Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomasInt J Cancer996771512115476 </plain></SENT>
</text></ref><ref id="b157-bmi-2007-447"><text><SENT sid="326" pm="."><plain>WoodmanCBJCollinsSIYoungLS2007The natural history of cervical HPV infection: unresolved issuesNature Rev Cancer7112217186016 </plain></SENT>
</text></ref><ref id="b158-bmi-2007-447"><text><SENT sid="327" pm="."><plain>WuAWiesnerSXiaoJ2006Expression of MHC I and NK ligands on human CD133(+) glioma cells: possible targets of immunotherapyJ Neurooncol </plain></SENT>
</text></ref><ref id="b159-bmi-2007-447"><text><SENT sid="328" pm="."><plain>YasunagaSGratiMCohen-SalmonM1999A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafnessNat Genet214363910192385 </plain></SENT>
</text></ref><ref id="b160-bmi-2007-447"><text><SENT sid="329" pm="."><plain>YeagerCLAshmunRAWilliamsRK1992Human aminopeptidase N is a receptor for human coronavirus 229ENature357637742021350662 </plain></SENT>
</text></ref><ref id="b161-bmi-2007-447"><text><SENT sid="330" pm="."><plain>YeeKWKeatingA2003Advances in targeted therapy for chronic myeloid leukemiaExpert Review of Anticancer Therapy329531012820774 </plain></SENT>
</text></ref><ref id="b162-bmi-2007-447"><text><SENT sid="331" pm="."><plain>YimE-KParkJS2006Biomarkers in cervical cancerBiomarker Insights221525 </plain></SENT>
</text></ref><ref id="b163-bmi-2007-447"><text><SENT sid="332" pm="."><plain>YinBWDnistrianALloydKO2002Ovarian cancer antigen CA125 is encoded by the MUC16 mucin geneInt J Cancer9857374011920644 </plain></SENT>
</text></ref><ref id="b164-bmi-2007-447"><text><SENT sid="333" pm="."><plain>YuJLinJHWuXR1994Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteinsJ Cell Biol1251171828138569 </plain></SENT>
</text></ref><ref id="b165-bmi-2007-447"><text><SENT sid="334" pm="."><plain>Zidi-YahiaouiNMouro-ChanteloupID’AmbrosioAM2005Human Rhesus B and Rhesus C glycoproteins: properties of facilitated ammonium transport in recombinant kidney cellsBiochem J391Pt 1334015929723 </plain></SENT>
</text></ref><ref id="b166-bmi-2007-447"><text><SENT sid="335" pm="."><plain>zur HausenH2002Papillomaviruses and cancer: from basic studies to clinical applicationNature Rev Cancer23425012044010 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="t1-bmi-2007-447" position="float"><label>Table 1</label><caption><p><text><SENT sid="336" pm="."><plain>Highly expressed genes with membrane-bound gene products up-regulated in cervical dysplasia stages CINI and CINIII. </plain></SENT>
<SENT sid="337" pm="."><plain>Up-regulated gene expression, from normal, ≥2-fold. </plain></SENT>
</text></p></caption><table-wrap-foot><fn id="tfn1-bmi-2007-447"><label>*</label><p>GEO Series Accession Numbers GSE6252. 1,101,702 total longSAGE tags in four normal libraries, GEO Alias N3, N1, N2, N4; 2,165,777 total longSAGE tags in six CINIII libraries, GEO Alias C1, C3, C2, C4, C5, C6; 785,642 total longSAGE tags in three CINI libraries, GEO Alias M1, M2, M3.</p></fn><fn id="tfn2-bmi-2007-447"><label>**</label><p>Mapping unable to be confirmed through ENSEMBL or BLAT.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t2-bmi-2007-447" position="float"><label>Table 2</label><caption><p><text><SENT sid="338" pm="."><plain>Highly expressed genes with membrane-bound gene products up-regulated in normal cervical tissue. </plain></SENT>
<SENT sid="339" pm="."><plain>Up-regulated gene expression, from CINI and/or CINIII, ≥2-fold. </plain></SENT>
</text></p></caption><table-wrap-foot><fn id="tfn3-bmi-2007-447"><label>*</label><p>GEO Series Accession Number GSE6252. 1,101,702 total longSAGE tags in four normal libraries, GEO Alias N3, N1, N2, N4; 2,165,777 total longSAGE tags in six CINIII libraries, GEO Alias C1, C3, C2, C4, C5, C6; 785,642 total longSAGE tags in three CINI libraries, GEO Alias M1, M2, M3.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
